(1Z,3Z)-1,3-Diazocine | 292-76-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环化合物
• 英文名称: (1Z,3Z)-1,3-Diazocine
• 英文别名: 1,3-diazocine
• CAS: 292-76-2
• 化学式: C₆H₆N₂
• 分子量: 106.13
• InChiKey: XQAWYOVBYNABFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE<br/>[FR] RÉACTIONS ORGANIQUES RÉALISÉES DANS UNE SOLUTION AQUEUSE EN PRÉSENCE D'UNE HYDROXYALKYL(ALKYL)CELLULOSE OU D'UNE ALKYLCELLULOSE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2017129796A1

  公开（公告）日：2017-08-03

  The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.

  本发明涉及在水溶液中在羟基烷基（烷基）纤维素或烷基纤维素存在下进行有机反应的方法。
• [EN] BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY<br/>[FR] AMIDES DE BENZOFURANE ET LEURS ANALOGUES HÉTÉROAROMATIQUES DESTINÉS À ÊTRE UTILISÉS EN THÉRAPIE
  申请人：EUROPEAN MOLECULAR BIOLOGY LABORATORY

  公开号：WO2018229193A1

  公开（公告）日：2018-12-20

  The present invention relatesto a pharmaceutical composition comprising acompound of the formula Ias described belowor a tautomeror a pharmaceutically acceptable salt thereof; to the compound of the formula Ias described below or a tautomer or a phar- maceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, and to certain novel compoundsof the formula Ias described below or a tautomer or a pharmaceuti- cally acceptable salt thereof. Formula (I) wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; with the proviso that at most two of X1, X2, X3 and X4 are N; L1, L2 are a bond or a bivalent radical such as C1-C6-alkylene or C3-C8-cycloalkylene; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring which may carry one or more substituents R9; or L2-A forms a group C1-C6-alkylene-OR13, C1-C6-alkylene-SR14 or C1-C6-alkylene-NR15R16; and R1, R2, R3, R4, R5, R6, R9, R13, R14, R15 and R16 are as defined in the claims and the description.

  本发明涉及一种药物组合物，包括下述的化合物I的构造或其互变异构体或药用盐；以及用作药物的下述的化合物I的构造或其互变异构体或药用盐，特别用于治疗或预防从炎症性疾病、过度增殖性疾病或紊乱、缺氧相关病理和以过度血管生成为特征的疾病中选择的疾病或紊乱；以及下述的某些新型化合物I的构造或其互变异构体或药用盐。其中，化合物(I)中X1为CR1或N；X2为CR2或N；X3为CR3或N；X4为CR4或N；但X1、X2、X3和X4中最多有两个为N；L1、L2为键或类似C1-C6-烷基或C3-C8-环烷基的二价基团；A为3-、4-、5-、6-、7-或8-成员饱和、部分不饱和或最大不饱和的碳环，可能携带一个或多个取代基R9；或L2-A形成一个基团C1-C6-烷基-OR13、C1-C6-烷基-SR14或C1-C6-烷基-NR15R16；而R1、R2、R3、R4、R5、R6、R9、R13、R14、R15和R16如权利要求和说明中所定义。
• HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150259343A1

  公开（公告）日：2015-09-17

  The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor, and processes for preparing such compounds and compositions.

  本发明涉及携带环状取代基的三环六氢二氮杂喹啉类化合物，以及生产它们的方法，含有这类化合物的药物组合物，它们作为5-HT2C受体的调节剂，特别是激动剂或部分激动剂的用途，用于制备用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的药物，用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的方法，以及制备这类化合物和组合物的方法。
• [EN] BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY<br/>[FR] BENZOFURANE-URÉES OU CARBAMATES ET ANALOGUES HÉTÉROAROMATIQUES DE CEUX-CI DESTINÉS À ÊTRE UTILISÉS EN THÉRAPIE
  申请人：EUROPEAN MOLECULAR BIOLOGY LABORATORY

  公开号：WO2018229194A1

  公开（公告）日：2018-12-20

  The present invention relates to benzofuran ureas or carbamates of formula I and heteroaromatic analogues thereof as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing these compounds, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Formula (I) wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; with the proviso that at most two of X1, X2, X3 and X4 are N; E1 is O or NR6a; E2 is O or NR6b;with the proviso that E1 and E2 are not simultaneously O; L1 is a bond, optionally substituted C1-C6-alkylene or C3-C8-cycloalkylene; L2 is a bond, optionally substituted C1-C6-alkylene, C3-C8-cycloalkylene, etc.; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring or a 3-, 4-, 5-, 6-, 7- or 8- membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring; or L2-A forms a group C1-C6-alkylene-OR13, C1-C6--alkylene-SR14 or C1-C6-alkylene-NR15R16; and R1, R2, R3, R4, R5, R6a, R6b, R13, R14, R15 and R16 are as defined in the claims and the description.

  本发明涉及如下所述的苯并呋喃脲或卡巴酯的化合物，以及其杂芳类似物或其互变异构体或药学上可接受的盐；含有这些化合物的药物组合物；以及这些化合物在治疗中的用途，特别是用于治疗或预防来自炎症性疾病、高增殖性疾病或紊乱、缺氧相关病理和以过度血管化为特征的疾病中所选择的疾病或紊乱。其中，X1为CR1或N；X2为CR2或N；X3为CR3或N；X4为CR4或N；但X1、X2、X3和X4中至多两个为N；E1为O或NR6a；E2为O或NR6b；但E1和E2不能同时为O；L1为键，可选择地取代的C1-C6烷基或C3-C8环烷基；L2为键，可选择地取代的C1-C6烷基、C3-C8环烷基等；A为3、4、5、6、7或8-成员饱和、部分不饱和或最大不饱和的碳环或3、4、5、6、7或8-成员饱和、部分不饱和或最大不饱和的杂环；或L2-A形成一个基团C1-C6-烷基-OR13、C1-C6-烷基-SR14或C1-C6-烷基-NR15R16；R1、R2、R3、R4、R5、R6a、R6b、R13、R14、R15和R16如权利要求和说明所定义。
• [EN] HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL<br/>[FR] HEXAHYDRODIAZÉPINOQUINOLÉINES PORTANT UN RADICAL ALKYLE SUBSTITUÉ
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2015136091A1

  公开（公告）日：2015-09-17

  The present invention relates to tricyclic hexahydrodiazepinoquino lines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5- HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.

  本发明涉及携带取代烷基基团的三环六氢二氮杂喹诺喹啉类化合物，以及生产它们的方法，含有这类化合物的药物组合物，它们作为5-HT2C受体的调节剂，特别是激动剂或部分激动剂的用途，用于制备用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的药物，用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的方法，以及制备这类化合物和组合物的过程。